RiffOn - Smart Biotech Scientist | Master Bioprocess CMC Development, Biologics Manufacturing & Scale-up, Cell Culture Innovation

Episodes

244: Prevent the Delays That Derail Biologics Tech Transfer: 12-Week Protocol for CMC

April 16, 2026

Prevent biologics tech transfer delays with a 12-week protocol focusing on stakeholder management, technical de-risking, and delegation.

243: Turn Tech Transfer from a Gamble into a Managed Process: The 6-Pillar Biologics Scale-Up Framework

April 14, 2026

Turn biologics tech transfer from a high-stakes gamble into a managed process with a robust 6-pillar framework for successful scale-up.

242: DMSO in Cell Therapy: Why Viability Scores Hide the Real Toxicity with Steve Oh - Part 2

April 9, 2026

A new cryopreservation solution outperforms toxic DMSO, improving cell viability, function, and simplifying cell therapy manufacturing workflows.

241: DMSO in Cell Therapy: Why Viability Scores Hide the Real Toxicity with Steve Oh - Part 1

April 7, 2026

DMSO, the 60-year cryopreservation standard, is effective but toxic, compromising modern cell therapies. Viability scores mask its true damage.

240: Continuous Microbial Manufacturing: From Genetic Instability to 40-Day E. coli Processes with Juergen Mairhofer - Part 2

April 2, 2026

The bioprocessing CDMO model is broken. Innovation in continuous manufacturing is the only way to survive Asian competition and big pharma shifts.

239: Continuous Microbial Manufacturing: From Genetic Instability to 40-Day E. coli Processes with Juergen Mairhofer - Part 1

March 31, 2026

CEO Juergen Mairhofer on overcoming E. coli's genetic instability for 40-day continuous manufacturing by decoupling growth and production.

238: High-Throughput Microbial Screening: Avoiding Early Mistakes That Derail Scale-Up with Sebastian Blum - Part 2

March 26, 2026

High-throughput screening isn't a simple 'black box.' It's a complex tool requiring deep expertise to avoid costly scale-up mistakes.

237: High-Throughput Microbial Screening: Avoiding Early Mistakes That Derail Scale-Up with Sebastian Blum - Part 1

March 24, 2026

Avoid costly scale-up failures by optimizing early bioprocess screening. This episode compares high-throughput systems vs. traditional methods.

236: Plant-Based Biomanufacturing: How Molecular Farming Produces Biopharmaceuticals in Weeks, Not Months with Waranyoo Phoolcharoen - Part 2

March 19, 2026

Molecular farming uses plants for rapid biopharma production, offering a low-cost, scalable alternative to traditional CHO and microbial systems.

235: Plant-Based Biomanufacturing: How Molecular Farming Produces Biopharmaceuticals in Weeks, Not Months with Waranyoo Phoolcharoen - Part 1

March 17, 2026

Professor Waranyoo Phoolcharoen explains molecular farming, a method using plants as biofactories to produce biopharma in weeks, not months.

234: Why Most Bioprocess Automation Projects Fail Before the Robot Is Even Ordered with Anthony Catacchio - Part 2

March 12, 2026

De-risk bioprocess automation by prioritizing upfront validation and a 'Minimum Testable Product' to find fatal flaws before costly engineering.

233: Why Most Bioprocess Automation Projects Fail Before the Robot Is Even Ordered with Anthony Catacchio - Part 1

March 10, 2026

Most bioprocess automation projects fail from poor problem definition, not technology. Success lies in understanding the process first.

232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann - Part 2

March 5, 2026

Master Biologics CMC from IND to BLA using the house analogy. Solid foundations and robust process validation determine regulatory success.

231: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann - Part 1

March 3, 2026

Biologics development is like building a house. Your Phase 1 CMC decisions form an irreparable foundation for regulatory success. Get it right.

230: Cyanobacteria Biomanufacturing: Achieving Carbon-Neutral Production at Lower Cost Than Fermentation with Tim Corcoran - Part 2

February 26, 2026

Deep Blue Biotech's strategy for scaling cyanobacteria production: partner with CMOs, build a pilot plant, then license for mass-market reach.

229: Cyanobacteria Biomanufacturing: Achieving Carbon-Neutral Production at Lower Cost Than Fermentation with Tim Corcoran - Part 1

February 24, 2026

CEO Tim Corcoran reveals how cyanobacteria enable carbon-neutral biomanufacturing at lower costs than fermentation for high-value chemicals.

228: Media-Based Glycan Engineering for Biosimilars: Your Rapid Implementation Guide

February 17, 2026

Master glycan engineering with raffinose. This guide provides an 8-week, 3-experiment protocol to increase high mannose for biosimilar matching.

227: Media-Based Glycan Engineering for Biosimilars: Achieving Reference Product Match

February 10, 2026

Raffinose in media increases high-mannose glycans 2.8x, solving biosimilar glycan mismatch without cell re-engineering or inhibitors.

226: Mastering Radiopharmaceutical Development: Preclinical Model Selection for Clinical Success with Bryan Miller - Part 2

February 5, 2026

Radiopharmaceuticals are entering a new era, driven by theragnostics, advanced preclinical models (PDX), and strategic CRO partnerships.

225: Mastering Radiopharmaceutical Development: Preclinical Model Selection for Clinical Success with Bryan Miller - Part 1

February 3, 2026

Mastering radiopharmaceutical development requires precise preclinical models to overcome unique challenges in this rapidly growing oncology field.

224: From Cultivated Meat to Chocolate: Rethinking Cellular Agriculture Scale-Up with Steven Lang - Part 2

January 29, 2026

Cellular agriculture is more than lab meat. Explore scaling cacao & coffee to meet global food demand, focusing on simpler, safer products.

223: From Cultivated Meat to Chocolate: Rethinking Cellular Agriculture Scale-Up with Steven Lang - Part 1

January 27, 2026

Steven Lang of California Cultured explains how producing cacao from plant cells offers a cost-effective, scalable vision for cellular agriculture.

222: From 2D Cultures to Advanced 3D Cell Models for Preclinical Research with Catarina Brito - Part 2

January 22, 2026

Advanced 3D cell models reveal therapeutic resistance missed by 2D cultures, offering a more predictive preclinical research platform.

221: From 2D Cultures to Advanced 3D Cell Models for Preclinical Research with Catarina Brito - Part 1

January 20, 2026

Catarina Brito explains why bioprocess must be biology-first, pioneering advanced 3D cell models to replace traditional preclinical methods.

220: From 10,000 Structures to 1.8 Billion Interactions: Breaking the Data Bottleneck to Engineer Efficacious Therapeutics with Troy Lionberger - Part 2

January 15, 2026

From 10k structures to 1.8B interactions, A-alpha Bio's platform breaks the data bottleneck, fueling AI to engineer complex therapeutics.

219: From 10,000 Structures to 1.8 Billion Interactions: Breaking the Data Bottleneck to Engineer Efficacious Therapeutics with Troy Lionberger - Part 1

January 13, 2026

A-AlphaBio's Troy Lionberger explains how measuring millions of protein interactions and using AI transforms antibody discovery from years to months.

Smart Biotech Scientist | Master Bioprocess CMC Development, Biologics Manufacturing & Scale-up, Cell Culture Innovation